ArticleBiotechnology progress
An efficient and robust strategy for developing cell lines through targeted integration.
Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reducing the time needed and enhancing predictability of outcomes for cell line development is an ongoing focus of improvement. Targeted integration (TI) where the expression cassettes for a biologic are inserted at a predefined locus, a landing pad, is one of the strategies that is used for this purpose. To be commercially viable the landing pad host cell must support high titers and the transgenes in the landing pad must be highly transcribed. To make such a host TI cell line takes a great deal of time and effort with little guarantee of success. Here we describe a strategy where we converted a stable high-expressing mAb cell line and generated multiple TI host cell lines that are commercially relevant. We routinely generate 6 g/L mAb clones using our platform fit process and 8 to >10 g/L with process optimization that are phenotypically and genetically stable. We also created a duo-landing pad where both landing pads reside in the same locus. This gives the opportunity to simplify the construction of differentially expressed genes since both landing pads are expected to perform equally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.